Vasculitis News and Research

Latest Vasculitis News and Research

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Nanogels are synthetic particles that can be used for drug delivery. They are approximately 100 nm to 200 nm in diameter, and are made from safe, biocompatible materials: a gel-like interior and a lipid exterior.

24 Apr 2013

Tissue damage causes unexplained pain among metal-on-metal hip implant patients

The cause of unexplained pain among metal-on-metal hip implant patients is more likely to be tissue damage than wear of the implant, Hospital for Special Surgery researchers have found.

20 Mar 2013

Columbia University Medical Center, NewYork-Presbyterian Hospital present research works at AAN meeting

The following research from Columbia University Medical Center and NewYork-Presbyterian Hospital is being presented at the 65th annual meeting of the American Academy of Neurology, March 16-23, 2013, in San Diego.

18 Mar 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Circulating endothelial cells hit the mark in primary central nervous system vasculitis

Circulating endothelial cells may be a promising, non-invasive means of diagnosing and monitoring primary central nervous system vasculitis, researchers report.

2 Jan 2013

Vasculitis and the metabolic syndrome frequently co-exist

The metabolic syndrome is significantly more common in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis than healthy individuals, researchers have found.

3 Dec 2012

Brain microhemorrhages more common among high altitude cerebral edema survivors

New magnetic resonance imaging (MRI) research shows that mountain climbers who experience a certain type of high altitude sickness have traces of bleeding in the brain years after the initial incident, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

28 Nov 2012

Anti-TNF-α therapy reduces CVD risk in patients with rheumatoid arthritis

Patients with rheumatoid arthritis exhibit a sub-clinical vasculitis that may underlie their increased risk for cardiovascular disease, shows research.

5 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Clinical and demographic factors impact visual acuity in retinal vasculitis

Just over one-third of individuals with retinal vasculitis will experience vision loss despite undergoing therapy for the condition, while approximately the same proportion will experience some improvement, show study results.

19 Oct 2012

ANCA-associated vasculitis not a single clinical entity

Study findings show distinct subtypes of antineutrophil cytoplasmic antibody-associated vasculitis, distinguished by the target of autoantigen reactivity.

25 Jul 2012

Anthera announces final set of clinical data from blisibimod Phase 2b study on SLE

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced the final set of clinical data from the Phase 2b PEARL-SC study in patients with systemic lupus erythematosus.

17 Jul 2012

Anthera announces results from blisibimod Phase 2b study on SLE

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced results from the Phase 2b PEARL-SC clinical study in patients with systemic lupus erythematosus.

28 Jun 2012

SQI Diagnostics reports net loss of $1,350,000 for second quarter 2012

SQI Diagnostics Inc., a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced its financial and operational results for the three and six months ended March 31, 2012.

31 May 2012

Patients prefer immediate access to radiology reports

You've been experiencing severe back pain and weakness in your right leg. Your doctor orders a spinal MRI to help determine the cause. The radiology report diagnoses cancer. Would you rather read the detailed medical report right away at home or wait until your doctor was available to explain the test results, diagnosis and treatment options? This scenario was part of a study at Wake Forest Baptist Medical Center designed to determine if patients wanted online access to radiology test results and, if so, how quickly.

3 Apr 2012

ChemoCentryx fourth quarter revenues increase to $26.1 million

ChemoCentryx, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2011.

31 Mar 2012

AARDA hopes to educate public on autoimmune diseases during March

March is National Autoimmune Diseases Awareness Month, and the American Autoimmune Related Diseases Association (AARDA) is working to educate the public on risk factors, prevalence, and the severe lack of awareness surrounding autoimmune diseases.

3 Mar 2012

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Human Genome Sciences, Inc. will today announce its priority goals for 2012 and report on progress with the commercialization of BENLYSTA (belimumab), the first approved drug for systemic lupus in 56 years, during a presentation this afternoon by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 30th Annual JPMorgan Healthcare Conference in San Francisco.

9 Jan 2012

GSK obtains exclusive license to ChemoCentryx's CCX354 CCR1 inhibitor for RA

ChemoCentryx, Inc., today announced that GlaxoSmithKline (GSK) has exercised its option to obtain an exclusive license for further development and worldwide commercialization of the investigational medicine CCX354, a potent and selective inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis (RA).

6 Jan 2012

ChemoCentryx commences CCX140 Phase II trial in diabetic nephropathy

ChemoCentryx, Inc. today announced the initiation of a Phase II clinical trial for CCX140, an orally-administered small molecule for the treatment of diabetic kidney disease.

9 Dec 2011

Vasculitis News and Research

Latest Vasculitis News and Research

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Tissue damage causes unexplained pain among metal-on-metal hip implant patients

Columbia University Medical Center, NewYork-Presbyterian Hospital present research works at AAN meeting

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Circulating endothelial cells hit the mark in primary central nervous system vasculitis

Vasculitis and the metabolic syndrome frequently co-exist

Brain microhemorrhages more common among high altitude cerebral edema survivors

Anti-TNF-α therapy reduces CVD risk in patients with rheumatoid arthritis

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Clinical and demographic factors impact visual acuity in retinal vasculitis

ANCA-associated vasculitis not a single clinical entity

Anthera announces final set of clinical data from blisibimod Phase 2b study on SLE

Anthera announces results from blisibimod Phase 2b study on SLE

SQI Diagnostics reports net loss of $1,350,000 for second quarter 2012

Patients prefer immediate access to radiology reports

ChemoCentryx fourth quarter revenues increase to $26.1 million

AARDA hopes to educate public on autoimmune diseases during March

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

GSK obtains exclusive license to ChemoCentryx's CCX354 CCR1 inhibitor for RA

ChemoCentryx commences CCX140 Phase II trial in diabetic nephropathy

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Vasculitis News and Research

Latest Vasculitis News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in